Chris N. Barnes

Statistics

Publications

Citations

H-Index

Active since

2017

Affiliations

Theravance Biopharma (United States)(Current)

Clinical Research Institute

Chris N. Barnes is an author at Theravance Biopharma (United States) specializing in pharmacology, long-acting muscarinic antagonists, and chronic obstructive pulmonary disease pharmacotherapy.

Publications per year

2017–2019

Publications

Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow Rate

Donald A. Mahler, Jill Ohar, Chris N. Barnes et al. · Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation · 2019 · 33 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease

Krishna Pudi, Chris N. Barnes, Edmund J. Moran et al. · Respiratory Research · 2017 · 32 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)

James F. Donohue, Edward Kerwin, Sanjay Sethi et al. · Respiratory Research · 2019 · 19 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Revefenacin, a Long‐Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo‐ and Positive‐Controlled Thorough QT Study

Marie T. Borin, Chris N. Barnes, Börje Darpö et al. · Clinical Pharmacology in Drug Development · 2019 · 13 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

1–4 of 4